Plain-English translation of NCT04807894 on ClinicalTrials.gov β Β· Source last updated Β· Translation generated Β· How we translate trials
Phase 4 β The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial tested whether vaginal testosterone cream could help postmenopausal women who get frequent urinary tract infections (UTIs). After menopause, hormonal changes in the vagina can make women more prone to repeated bladder infections. The study compared women using vaginal testosterone cream to women using a placebo cream to see if the medication reduced how often UTIs occurred.
Postmenopausal women have a significantly higher risk of repeated UTIs due to hormonal changes in the vagina. While vaginal estrogen cream is known to help, many women cannot or prefer not to use itβso researchers wanted to see if this medication could offer an alternative way to prevent these painful, recurring infections.
You would apply the cream (or placebo) to your vagina once nightly for the first two weeks, then twice weekly for the remaining eight months of the study. During your participation, you would have vaginal exams and swabs to check your vaginal health, measurements of vaginal pH, and monitoring for UTI symptoms. The study lasted about nine months total across two medical centers.
AI-generated summary from trial data Β· Oct 7, 2026 Β· Not medical advice
United States
Post-approval monitoring
Sponsor
Jefferson Drapkin
Collaborators
American Urological Association
Enrollment target
~67 participants
Started
November 2020
Primary completion
August 2026
Age range
60 Years β 90 Years
Sex
Female only
Last updated on clinicaltrials.gov in September 2026.